2010 New Antimicrobial Drug Discovery and Development Gordon Research Conference

2010新型抗菌药物发现与开发戈登研究会议

• 批准号: 7906349
• 负责人: George Louis Drusano
• 金额: $ 1.5万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7906349
• 关键词: Academia; Accident and Emergency department; Acinetobacter; Antibiotics; Carbapenems; Colistin; Communities; Development; Enzymes; Escherichia coli; Eye; Hearing; Industry; Infection; Intensive Care Units; International; Klebsiella; Lactamase; Licensing; Macrolides; Measures; Monobactams; Organism; Postdoctoral Fellow; Predisposition; Prevalence; Process; Pseudomonas aeruginosa; Research; Resistance; Resistance profile; Science; Scientist; Site; Staphylococcus aureus; Streptococcus pneumoniae; Structure; Therapeutic Intervention; United States; Voice; antimicrobial; antimicrobial drug; drug discovery; meetings; member; methicillin resistant Staphylococcus aureus; pathogen; symposium

DESCRIPTION (provided by applicant): This Gordon Conference is aimed at a serious national and international problem: the lack of new antimicrobial agents for multi-resistant infections. In both the Intensive Care Unit (ICU) and the Community, organisms that commonly cause serious infections have become resistant to many of our most effective antibiotics. In the Community, organisms such as Streptococcus pneumonia have a rate of non- susceptibility to ¿-lactam antibiotics exceeding 20%. Other effective agents, such as macrolides, have resistance rates on the order of 40%. Community-Acquired MRSA has exploded in prevalence across the United States and is commonly seen in Emergency Departments. In the ICU, MRSA makes up approximately 50% of all Staphylococcus aureus infections and we have seen the advent of multi- resistant Gram-negative organisms, so that even common pathogens such as Klebsiella and E. coli may carry extended-spectrum ¿-lactamases, rendering them resistant to many of our best agents and, in the case of K-pc enzymes, this resistance profile includes carbapenems. In the case of Pseudomonas aeruginosa and Acinetobacter species, it is now reasonably common for an infecting pathogen to be resistant to all licensed antibiotics. A measure of our desperation is that we have resurrected 50 year-old, relatively toxic agents (colistin/polymixins) to have at least one available therapeutic intervention. In this Conference, we have a unique cross-disciplinary approach to the problem, where chemists, basic biologists and translational scientists meet and where Industry, Academia, Regulatory Agencies and political observers are all stakeholders and are invited to contribute to the interchange. Our past meetings have been scientifically rigorous and open, with both new science coming forward and the identification of bottlenecks in the process being part of the process. We have a conference where we are dedicated to the broadest participation and, in specific, are desirous of inclusion of younger members of the field at the post-doctoral level, to bring fresh perspective to the problems being examined. The site is well-suited for this interchange and the structure of the Conference follows the classical Gordon Conference format. The Discussion Leaders have been chosen with an eye toward generating robust, insightful discussion after the presentations. The format is democratic so that all voices will be heard and the emphasis will be on presenting the best and newest science and asking the correct questions to push the field forward. In this proposal, we ask for supplementary support for this important undertaking.

描述（由申请人提供）：本次戈登会议旨在解决一个严重的国家和国际问题：重症监护病房 (ICU) 和社区中缺乏针对多重耐药感染的新抗菌药物，这些微生物通常会导致严重的耐药性感染。感染已对我们许多最有效的抗生素产生耐药性。在社区中，肺炎链球菌等微生物对 ¿ - 内酰胺类抗生素的耐药率超过 20%，例如大环内酯类药物，社区获得性 MRSA 的耐药率在美国呈爆炸式增长，在急诊科中常见。约占所有金黄色葡萄球菌感染的 50%，而且我们已经看到多重耐药革兰氏阴性菌的出现，因此即使是克雷伯氏菌和大肠杆菌等常见病原体也同样如此。大肠杆菌可能携带广谱 ¿ -内酰胺酶，使它们对我们的许多最好的药物具有抗药性，对于 K-pc 酶，这种抗药性包括碳青霉烯类。对于铜绿假单胞菌和不动杆菌属，现在感染病原体相当常见。对所有获得许可的抗生素具有耐药性的一个衡量标准是，我们复活了 50 年历史的、毒性相对较大的药物（粘菌素/多粘菌素）。至少一种可用的治疗干预措施。 在这次会议上，我们对这个问题采取了独特的跨学科方法，化学家、基础生物学家和转化科学家齐聚一堂，工业界、学术界、监管机构和政治观察员都是利益相关者，并被邀请为我们的过去的交流做出贡献。会议在科学上是严谨和开放的，新的科学不断涌现，过程中瓶颈的确定也是该过程的一部分。 我们举办的会议致力于最广泛的参与，特别是希望吸收该领域的年轻博士后成员，为正在研究的问题带来新的视角。该网站非常适合。此次交流和会议的结构遵循经典的戈登会议形式，选择讨论领袖时着眼于在演讲后产生激烈、富有洞察力的讨论。这种形式是民主的，以便所有人的声音都能被听到，重点也将得到体现。致力于展示最好和最新的科学并提出问题在此提案中，我们请求为这项重要事业提供补充支持。